166 related articles for article (PubMed ID: 38250873)
1. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.
Bai S; Kang Y; Chen W; Xie H; Zhang L; Lv M; Wang J; Wu J; Zhao W
Viral Immunol; 2023 Oct; 36(8):526-533. PubMed ID: 37625037
[TBL] [Abstract][Full Text] [Related]
3. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
[TBL] [Abstract][Full Text] [Related]
4. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
5. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; GuimarĂ£es-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
7. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
[TBL] [Abstract][Full Text] [Related]
8. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
[TBL] [Abstract][Full Text] [Related]
9. Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants.
He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108216. PubMed ID: 34634689
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.
Sundaram AK; Ewing D; Liang Z; Jani V; Cheng Y; Sun P; Raviprakash K; Wu SJ; Petrovsky N; Defang G; Williams M; Porter KR
Pathogens; 2021 May; 10(5):. PubMed ID: 34069575
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
15. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Brook B; Chen J; Diray-Arce J; Doss-Gollin S; Leon M; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
bioRxiv; 2021 May; ():. PubMed ID: 34031655
[TBL] [Abstract][Full Text] [Related]
16. Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
Zheng X; Yang R; Zhao Y; Zhang Y; Yuan G; Li W; Xiao Z; Dong X; Ma M; Guo Y; Wang W; Zhao X; Yang H; Qiu S; Peng Z; Liu A; Yu S; Zhang Y
Virology; 2024 Jun; 594():110050. PubMed ID: 38479071
[TBL] [Abstract][Full Text] [Related]
17. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Villar MJ; Thimmiraju SR; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez P; Bottazzi ME
bioRxiv; 2022 Mar; ():. PubMed ID: 34268512
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
19. Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.
Haghighi M; Khorasani A; Karimi P; Mahdavi M
Iran J Basic Med Sci; 2022 May; 25(5):554-561. PubMed ID: 35911642
[TBL] [Abstract][Full Text] [Related]
20. Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2.
Shi J; Zhao Y; Peng M; Zhu S; Wu Y; Ji R; Shen C
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]